PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV)
CUSIP: 72941H509
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 179,252,507
- Total 13F shares
- 11,553,714
- Share change
- +4,072,839
- Total reported value
- $5,918,291
- Price per share
- $0.51
- Number of holders
- 27
- Value change
- +$1,886,508
- Number of buys
- 19
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 72941H509?
CUSIP 72941H509 identifies PSTV - PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 72941H509:
Top shareholders of PSTV - PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
0.81%
|
1,446,827
|
$989,630 | — | 30 Sep 2025 | |
| Altium Capital Management LLC |
13F
|
Company |
0.51%
|
918,914
|
$628,262 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
813,250
|
$556,018 | — | 30 Sep 2025 | |
| S.H.N. Financial Investments Ltd. |
13D/G
|
— |
1.5%
|
1,500,000
|
$525,000 | +$101,586 | 14 Aug 2025 | |
| UBS Group AG |
13F
|
Company |
0.35%
|
623,874
|
$426,730 | — | 30 Sep 2025 | |
| Orin Hirschman |
13D/G
|
— |
3.9%
|
1,283,681
|
$410,778 | +$231,288 | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.26%
|
469,389
|
$320,921 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.19%
|
341,893
|
$233,752 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.15%
|
265,489
|
$181,515 | — | 30 Sep 2025 | |
| Scientech Research LLC |
13F
|
Company |
0.08%
|
146,654
|
$100,267 | — | 30 Sep 2025 | |
| Robert P. Lenk |
3/4/5
|
Director |
—
mixed-class rows
|
437,121
mixed-class rows
|
$68,116 | +$53,779 | 22 Aug 2025 | |
| Greg Petersen |
3/4/5
|
Director |
—
mixed-class rows
|
113,553
mixed-class rows
|
$66,043 | — | 18 Feb 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.04%
|
67,264
|
$45,988 | — | 30 Sep 2025 | |
| Howard Clowes |
3/4/5
|
Director |
—
mixed-class rows
|
324,291
mixed-class rows
|
$35,405 | — | 13 Aug 2025 | |
| Richard J. Hawkins |
3/4/5
|
Director |
—
mixed-class rows
|
412,982
mixed-class rows
|
$22,767 | — | 13 Aug 2025 | |
| MERCER GLOBAL ADVISORS INC /ADV |
13F
|
Company |
0.02%
|
28,472
|
$19,466 | — | 30 Sep 2025 | |
| DAGCO, INC. |
13F
|
Company |
0.01%
|
25,882
|
$17,696 | — | 30 Sep 2025 | |
| Kestra Advisory Services, LLC |
13F
|
Company |
0.01%
|
25,800
|
$17,639 | — | 30 Sep 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.01%
|
11,659
|
$7,971 | — | 30 Sep 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.01%
|
11,078
|
$7,574 | — | 30 Sep 2025 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.01%
|
10,500
|
$7,000 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
3,520
|
$2,407 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
3,345
|
$2,287 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
831
|
$567 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
133
|
$59 | — | 30 Sep 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
53
|
$36 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
2
|
$1 | — | 30 Sep 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| An van Es-Johansson |
3/4/5
|
Director |
—
class O/S missing
|
297,794
|
— | — | 13 Aug 2025 | |
| Kyle Guse |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 13 Aug 2025 | |
| Norman D. LaFrance |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
24,073
|
— | — | 22 Feb 2024 |
Institutional Holders of PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV) as of Q4 2025
As of 31 Dec 2025,
PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,553,714 shares.
The largest 10 holders included
VANGUARD GROUP INC, L1 Global Manager Pty Ltd, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, UBS Group AG, Virtu Financial LLC, STATE STREET CORP, NORTHERN TRUST CORP, and XTX Topco Ltd.
This page lists
27
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
23
Q4 2025 holders
27
Holder diff
4
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.